Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
ID: 336094Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/336094

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-341.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) to support innovative research aimed at enhancing cancer control through behavioral modification, screening, and understanding the etiological factors of cancer. This funding opportunity encourages the submission of exploratory and developmental research grant applications that can significantly advance population-based cancer research, with a maximum budget of $275,000 available for a two-year project period, without the need for extensive preliminary data. The initiative emphasizes the importance of addressing public health challenges related to cancer epidemiology and health disparities, particularly encouraging participation from underrepresented groups in research. Applications are due by 5 PM local time on October 8, 2024, and interested applicants can find more information and guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-21-341-Full-Announcement.html
    PAR-21-341.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), has announced the Exploratory Grants in Cancer Control (R21 Clinical Trial Optional). This funding opportunity supports exploratory and developmental research projects aimed at advancing cancer control through behavioral modification, screening, and understanding cancer-related etiologic factors. The R21 mechanism provides a maximum budget of $275,000 for a two-year project period without requiring extensive preliminary data. Key research interests include cancer behavior modification, risk factor identification, and the development of innovative methodologies. Eligible applicants include higher education institutions, nonprofits, and government entities, with an emphasis on encouraging participation from underrepresented groups. Applications must adhere strictly to the NIH application guidelines and are due by 5 PM local time on specified dates. Projects focusing on basic cancer biology or the development of diagnostics or therapies are deemed nonresponsive and will not be considered. The call for proposals reflects a commitment to improving public health through funded research that addresses significant challenges in cancer epidemiology, health disparities, and care delivery. The overarching aim is to promote high-risk, high-reward research with the potential for substantial scientific and clinical impact.
    Similar Opportunities
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (R34), aimed at enhancing clinical trials focused on cancer prevention and control. This program seeks to address critical gaps in knowledge regarding study populations, interventions, and operational challenges, facilitating the collection of essential data to finalize protocols for future clinical trials. The initiative is particularly important for improving cancer-related health behaviors, screening, and the long-term outcomes of cancer survivors. Eligible applicants include a diverse range of organizations, with funding available up to $600,000 over three years, and applications are due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Basic Research in Cancer Health Disparities" under the R21 Exploratory/Developmental Research Grant mechanism. This initiative aims to support innovative research investigating the biological and genetic factors contributing to cancer health disparities among various racial and ethnic populations, with a focus on mechanistic studies and the development of new methodologies. The program is designed to foster collaboration among scientists and build a nationwide cohort dedicated to advancing the understanding of cancer disparities, ultimately leading to future R01 projects. Applications can be submitted starting September 16, 2024, with a budget cap of $275,000 over two years, and the closing date for submissions is November 16, 2024. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the "Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research" (R21 Clinical Trial Not Allowed). This funding opportunity aims to enhance diversity among early-stage and junior investigators in cancer research, particularly from groups that are underrepresented in the biomedical, behavioral, clinical, and social sciences. The initiative encourages innovative studies in cancer biology, with a maximum funding amount of $275,000 available over a two-year period, and applications must demonstrate scientific merit and innovation. The application window opens on May 17, 2024, with the first awards expected to be made in June 2024; interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering the Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) to support investigator-initiated clinical trials aimed at reducing the burden of cancer. This funding opportunity focuses on enhancing early detection, prevention, healthcare delivery, and survivorship improvements, explicitly excluding studies related to cancer diagnosis or oncologic therapies. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and tribal organizations, with applications due by 5:00 PM local time on January 5, 2024, and a maximum project period of five years. For further details, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the program's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-072.html.
    Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Modular R01s in Cancer Control and Population Sciences grant, aimed at advancing research in cancer-related fields. This funding opportunity encourages innovative studies in areas such as epidemiology, cancer survivorship, healthcare delivery, and digital health, with the goal of addressing critical barriers in cancer research and promoting diversity among research topics. Eligible applicants include a wide range of organizations, including historically black colleges, tribal governments, and community-based organizations, with funding available up to $250,000 per year for a maximum of five years. Interested parties should submit their applications by November 5, 2024, and can find more information at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Impacts of climate change across the cancer control continuum (R21 Clinical Trial Optional)" aimed at fostering innovative research on the intersection of climate change and cancer. This R21 Exploratory/Developmental Research Grant seeks to explore various aspects of cancer risks exacerbated by climate change, including environmental influences, healthcare disruptions, and health disparities, with a focus on multidisciplinary approaches and collaboration with climate change experts. The grant supports studies with budgets up to $275,000 over a two-year period, and eligible applicants include higher education institutions, nonprofits, state and local governments, and for-profit organizations. Interested parties should note that the application deadline is May 7, 2026, and can find more information at the provided link or contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.